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ABSTRACT Host cell factor 1 (HCF-1), encoded by the ubiquitously expressed
X-linked gene Hcfc1, is an epigenetic coregulator important for mouse development
and cell proliferation, including during liver regeneration. We used a hepatocyte-
speciﬁc inducible Hcfc1 knockout allele (called Hcfc1hepKO) to induce HCF-1 loss in
hepatocytes of hemizygous Hcfc1hepKO/Y males by 4 days. In heterozygous
Hcfc1hepKO/ females, owing to random X-chromosome inactivation, upon Hcfc1hepKO
allele induction, a 50/50 mix of HCF-1-positive and -negative hepatocyte clusters is
engineered. The livers with Hcfc1hepKO/Y hepatocytes displayed a 21- to 24-day ter-
minal nonalcoholic fatty liver (NAFL), followed by nonalcoholic steatohepatitis
(NASH) disease progression typical of severe NAFL disease (NAFLD). In contrast, in
livers with heterozygous Hcfc1hepKO/ hepatocytes, HCF-1-positive hepatocytes re-
placed HCF-1-negative hepatocytes and revealed only mild NAFL development. Loss
of HCF-1 led to loss of PGC1 protein, probably owing to its destabilization, and de-
regulation of gene expression, particularly of genes involved in mitochondrial struc-
ture and function, likely explaining the severe Hcfc1hepKO/Y liver pathology. Thus,
HCF-1 is essential for hepatocyte function, likely playing both transcriptional and
nontranscriptional roles. These genetically engineered loss-of-HCF-1 mice can be
used to study NASH as well as NAFLD resolution.
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Nonalcoholic fatty liver disease (NAFLD) encompasses a wide range of liver condi-tions caused by excessive fat accumulation or steatosis within hepatocytes (1–5).
NAFLD consists of two phases: a less severe state of nonalcoholic fatty liver (NAFL),
where patients develop hepatic steatosis, followed in a minority of patients by a more
severe nonalcoholic steatohepatitis (NASH) condition associated with steatosis, fol-
lowed by ﬁbrosis to cirrhosis and even hepatocellular carcinoma (HCC) (6–8). Although
steatosis is considered a hallmark of NAFLD, it is not clearly known how NAFLD
transitions from the simple steatosis of NAFL to NASH, although mitochondrial mal-
function has been implicated in a two-hit steatosis-followed-by-oxidative-stress hy-
pothesis (9, 10).
Surprisingly, despite the current large increases in the number of NAFLD patients in
most developed countries (11), very little is known about the mechanisms of this
disease, in part owing to the lack of suitable animal models for its study. Current models
include genetic (e.g., PTEN liver knockout), nutritional (e.g., high fat and methionine
and choline deﬁcient [MCD]), and combinations of the two (e.g., db/dbmice on an MCD
diet), but none of these recapitulate the entire NAFLD process (12–14) or take about
24 weeks to develop (15). Hence, alternative animal models would aid in elucidating the
mechanism of disease progression and identifying pharmacotherapeutic options for
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both its prevention and cure. Here, we show that hepatocyte-speciﬁc disruption of
HCF-1 function leads to a rapid recapitulation of NAFLD, including NASH.
HCF-1, encoded by the X-linked HCFC1 and Hcfc1 genes in human and mice,
respectively, is a conserved metazoan transcriptional coregulator that binds to the
transcriptional start sites of many genes (16, 17) and physically links sequence-speciﬁc
DNA-binding transcription factors with chromatin-modifying enzymes, such as mixed-
lineage leukemia (MLL) and Set1 histone H3 lysine 4 (H3K4) methyltransferases (for a
review, see reference 18).
HCF-1 in humans and mice has been implicated in both proliferative and nonpro-
liferative cell functions. It is important for cell proliferation in cell culture and in mice
during both embryogenesis and liver regeneration (19–23). Human clinical studies of
X-linked diseases, including mental disability and cobalamin disorder, have linked the
HCFC1 gene to nonproliferative functions (24–27). Furthermore, stabilization of PGC-1
by HCF-1 has been shown to promote glucose production in hepatocytes, and knock-
down of HCF-1 improves glucose homeostasis in diabetic mice (28).
Here, we investigated the long-term role of HCF-1 in the resting mouse liver by
induced hepatocyte-speciﬁc inactivation of its cognate gene, Hcfc1.
RESULTS
Rapid induction of loss of Hcfc1 expression in adult liver hepatocytes. To probe
HCF-1 function in adult livers, we induced, via tamoxifen-dependent Cre-mediated loxP
site recombination, deletion of Hcfc1 exons 2 and 3 in hepatocytes of hemizygous
males carrying the Albumin-Cre-ERT2tg transgene (generating the Hcfc1hepKO allele) as
described previously (22). Identically treated Hcfc1lox/Y males lacking the hepatocyte-
speciﬁc Albumin-Cre-ERT2 transgene served as controls, particularly for the prominent
effects of tamoxifen treatment alone. Tamoxifen treatment of heterozygous Hcfc1lox/
females carrying the Albumin-Cre-ERT2 transgene leads to patches of HCF-1-positive
and -negative cells owing to whether the Hcfc1hepKO allele is generated on the inactive
or active X chromosome, respectively (22).
To determine the time course of tamoxifen activation of the Hcfc1hepKO allele, we
assayed Hcfc1 transcripts by RNA-Seq of poly(A)-selected RNA (Fig. 1A; see also Fig. S1
in the supplemental material) and levels of HCF-1 protein by immunoﬂuorescence (Fig.
1B). Whereas RNA-Seq tags were readily detected for all Hcfc1 exons prior to tamoxifen
treatment (0d samples in Fig. 1A and Fig. S1A to C), in Hcfc1hepKO/Y males, exon 2 and
3 tags rapidly disappeared, as early as day 1 after treatment (Fig. 1A, arrows, and Fig.
S1C and Table S1), and tags containing a novel exon 1 to exon 4 splice junction
appeared (Table S1). In contrast, there was no change in Hcfc1 expression in tamoxifen-
treated control Hcfc1lox/Y livers (Fig. S1A and Table S1). In Hcfc1hepKO/ heterozygous
females, the loss of exon 2 and 3 tags was less drastic, yet the exon 1 to 4 splice junction
tags diagnostic of Hcfc1hepKO allele generation were evident (Fig. S1B and Table S1),
indicating heterozygous Hcfc1hepKO allele generation.
The rapid disappearance of the wild-type Hcfc1 transcript after tamoxifen treatment
indicates that the synthesis of HCF-1 in hepatocytes is likewise rapidly blocked. In
cultured cells, HCF-1 has a long half-life (29). Consistent with such stability, progressive
and signiﬁcant hepatocyte-speciﬁc (i.e., HNF4 positive) reduction in HCF-1 protein
levels was seen in knockout males from day 2 onwards with an apparent complete
absence by day 7 (Fig. 1B, arrows). In contrast, non-hepatocyte HNF4-negative cells
continued to show high HCF-1 levels (Fig. 1B). Loss of HCF-1 was also detected at its
many genomic binding sites (see below). For example, here (Fig. 1C) we show HCF-1
bound to the Hcfc1 promoter at day 0, which is already lost by day 4. Interestingly, as
hepatocyte HCF-1 levels decreased in Hcfc1hepKO/Y males and Hcfc1 promoter-bound
HCF-1 disappeared, the levels of deleted Hcfc1hepKO transcripts increased (Fig. 1A and
Fig. S1), suggesting that the Hcfc1 gene is under negative HCF-1 autoregulation.
Loss of hepatocyte Hcfc1 expression leads to liver pathology. As a ﬁrst measure
of liver-speciﬁc pathology upon Hcfc1hepKO allele generation, we measured levels of the
liver injury marker aspartate aminotransferase (AST) in serum (Fig. 1D). Whereas AST
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FIG 1 Hcfc1hepKO/Y males display rapid loss of wild-type Hcfc1 expression in hepatocytes and subsequent liver pathology. (A) View
of the reads mapped on the 26 exons of the Hcfc1 gene, shown in blue at the top, in control (day 0 [0d]) liver and Alb-Cre-ERT2tg;
(Continued on next page)
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levels remained stable in control Hcfc1lox/Y males and initially in Hcfc1hepKO/Y males, by
8 days there was a large increase in the Hcfc1hepKO/Y males (Fig. 1D) following loss of
HCF-1 protein (Fig. 1B and C). In contrast, in Hcfc1hepKO/ heterozygous females, there
was only a brief marginal increase in AST levels at 8 days after tamoxifen treatment (Fig.
1D), indicating only a mild pathological response to heterogeneous HCF-1 loss in
hepatocytes.
With time, the Hcfc1hepKO/Y male livers became larger and paler as well as visibly
fatty (Fig. 1E), and the liver-to-body weight ratio increased considerably by 18 days after
tamoxifen treatment (Fig. S2B). Nevertheless, the body weight of Hcfc1hepKO/Y males
remained largely unaffected through 14 days after tamoxifen treatment, with a mar-
ginal decrease observed from 15 days onward (Fig. S3A). Such overt pathologies were
not observed in heterozygous Hcfc1hepKO/ female mice or livers (Fig. S2A and C).
Furthermore, while Hcfc1hepKO/ females appeared healthy and survived, the
Hcfc1hepKO/Y males appeared ill by 18 days after tamoxifen treatment and did not
survive beyond 21 to 24 days after tamoxifen treatment.
To probe further any effects of universal hepatocyte loss of HCF-1 in Hcfc1hepKO/Y
males or of heterogeneous hepatocyte HCF-1 loss in Hcfc1hepKO/ females, we per-
formed carbohydrate metabolism tests (Fig. S3B to G) and measured liver metabolite
concentrations (Fig. S4). Compared to control males, in a glucose tolerance test, the
Hcfc1hepKO/Y males did not show any initial difference in blood glucose levels and,
moreover, retained a healthy response (Fig. S3B), as did control and heterozygous
Hcfc1hepKO/ females (Fig. S3C). Consistent with these results, there were no signiﬁcant
differences in basal or glucose-stimulated insulin secretion levels between control and
Hcfc1hepKO/Y males (Fig. S3F), and they likewise responded similarly to an insulin
tolerance test (Fig. S3G), indicating that the Hcfc1hepKO/Y males are insulin sensitive.
In contrast, in pyruvate tolerance tests, the Hcfc1hepKO/Y males were defective for
gluconeogenesis (Fig. S3D), a defect that was signiﬁcantly less pronounced in heterozy-
gous Hcfc1hepKO/ females (Fig. S3E). In accordance with this Hcfc1hepKO/Y gluconeo-
genesis defect, we observed a reduction in the levels of dihydroxyacetone phosphate
(DHAP) and 3-phosphoglycerate (3-PGA), two intermediates in the gluconeogenesis
pathway, in Hcfc1hepKO/Y versus control males (Fig. S4A) and an overall increase in
glycogenolysis intermediates (i.e., glucose-1-phosphate, glucose-6-phosphate, and
fructose-6-phosphate; referred to here as Hex-P) (Fig. S4A).
Hence, biochemical, morphological, and metabolic analyses all indicated that
Hcfc1hepKO/Y males succumb to liver damage culminating in death, whereas
Hcfc1hepKO/ females with heterogeneous HCF-1 loss display transient alterations that
return to normalcy.
Hcfc1hepKO/Y males display characteristic NAFL progression to NASH of NAFLD.
To deﬁne the nature of the liver damage, we performed comparative histology of the
control and Hcfc1hepKO/Y males. As the Hcfc1hepKO/Y male livers appeared pale and fatty
(Fig. 1E), we ﬁrst performed Oil Red O staining to probe for steatosis. Indeed, the
Hcfc1hepKO/Y males displayed increased steatosis by 4 days (Fig. 2A). Lipid droplets were
widespread and increased over time. Consistent with increased lipid content, metabo-
lomic analyses at 7 days revealed elevated levels of fatty acid oxidation intermediates
in the form of short-, medium-, and long-chain acylcarnitines (Fig. S4B). By 18 days, the
FIG 1 Legend (Continued)
Hcfc1hepKO/Y livers 1, 2, and 4 days (1d, 2d, and 4d, respectively) after tamoxifen treatment according to RNA-Seq analysis. Arrows
point to the reads observed at Hcfc1 exons 2 and 3. The total relative Hcfc1 transcript expression level is listed to the right. (B)
Immunoﬂuorescence analysis of parafﬁn-embedded sections from control (0d) liver and Alb-Cre-ERT2tg; Hcfc1hepKO/Y livers 2, 4,
and 7 days after tamoxifen treatment and stained with 4’,6-diamidino-2-phenylindole (DAPI) (blue) together with antibodies
against HCF-1 (green) and HNF4 (red). Arrows point to hepatocytes. Scale bars, 50 m. (C) Image of HCF-1 ChIP-Seq reads
mapped onto the Hcfc1 gene from control (0d) and Alb-Cre-ERT2tg; Hcfc1hepKO/Y livers 4 days after tamoxifen treatment (4d). TSS,
transcription start site. (D) AST levels in control Hcfc1lox/Y (blue; n  3/time point), Alb-Cre-ERT2tg; Hcfc1hepKO/ (green; n  3/time
point), and Alb-Cre-ERT2tg; Hcfc1hepKO/Y (red; n  3/time point) livers at 0, 4, 8, 14, and 17 days after tamoxifen treatment. (E)
Macroscopic comparison of control liver (0d) and tamoxifen-treated knockout Alb-Cre-ERT2tg; Hcfc1hepKO/Y livers after 7, 14, and
18 days. Scale bar, 1 cm.
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steatosis was particularly severe, yet we noted clusters of hepatocytes with reduced fat
content near hepatic veins, as discussed further below (Fig. 2A, outlined areas). The
increase in liver fat content was reﬂected systemically by increased levels of circulating
blood serum triglycerides and high-density lipoprotein (HDL), low-density lipoprotein
(LDL), and total cholesterol already by 4 days (Fig. 2B). These increased lipid-associated
properties are typical of NAFLD progression (2).
Also associated with hepatocellular injury, hyperlipidemia, and NAFLD progression
is faulty bile acid secretion and amino acid accumulation (30, 31). Indeed, Hcfc1hepKO/Y
males possessed increased concentrations of a number of bile acids at 7 days after
tamoxifen treatment (Fig. S4C). Furthermore, several amino acids (e.g., glutamine,
glutamate, histidine, and serine) were elevated in Hcfc1hepKO/Y males at 7 days (Fig.
S4D).
The aforementioned metabolic disorders indicate a severe and rapid destabilization
of hepatocyte function upon the loss of HCF-1. To characterize the course of the
pathology, we performed histology for an array of markers affected by NAFLD progres-
sion. Figure 3 compares unaffected livers at day 0 and highly diseased livers at 18 days
after Hcfc1hepKO/Y induction; examples of intermediate states for many of the histolog-
ical analyses are shown in Fig. 5 to 8. Hematoxylin and eosin (H&E) staining (Fig. 3A and
Fig. S5) showed (i) marked tissue disorganization and breakdown of extracellular matrix
by 7 days, (ii) increased inﬂammatory cell inﬁltration, (iii) heterogeneous hepatocyte
nuclear sizes, referred to as nuclear anisocytosis or dysplasia (arrows), and (iv) often a
FIG 2 Hcfc1hepKO/Y males display increased steatosis. (A) Steatosis was measured by Oil Red O staining of cryosections from control
liver (0d) and tamoxifen-treated Alb-Cre-ERT2tg; Hcfc1hepKO/Y livers 4, 7, 14, and 18 days after treatment. Dotted lines outline hepatocyte
clusters with reduced levels of fat accumulation. Scale bar, 50 m. (B) Box plots of circulating triglyceride, total cholesterol, and HDL
and LDL cholesterol levels in control Hcfc1lox/Y (n  6) compared to Alb-Cre-ERT2tg; Hcfc1hepKO/Y (n  6) livers 4 days after tamoxifen
treatment. The differences between the levels of triglycerides (P value of 0.02), total cholesterol (P value of 4.2 104), and HDL (P
value of 4.6 104) and LDL (P value of 1.13 105) cholesterol in control and knockout livers were signiﬁcant.
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ballooning phenotype of hepatocytes; all of these signs are typical of extensive liver
injury. Coimmunostaining for the plasma membrane marker -catenin and HCF-1 (Fig.
3B) revealed, in addition to many of the aforementioned phenotypes, the general
restriction of HCF-1 to nonhepatocytes at 18 days.
Hepatic glycogen content is markedly reduced in carbon tetrachloride-induced rat
cirrhosis (32) and human cirrhotic patients (32). Periodic acid-Schiff (PAS) staining for
glycogen in the Hcfc1hepKO/Y male livers (Fig. 3C and Fig. S6) showed a progressive
decline in glycogen content beginning by 7 days with a drastic reduction observed at
18 days, consistent with hepatocyte dysfunction.
Inﬂammation, transformation of the liver sinusoidal endothelium into a continuous
vascular type, and activation of stellate cells resulting in ﬁbrosis are key hallmarks of
FIG 3 Hcfc1hepKO/Y males display characteristics typical of NASH by 18 days after tamoxifen treatment. (A to H)
Comparison of parafﬁn-embedded sections (A to D and F to H) and cryosections (E) of control livers (0d; left) and
Alb-Cre-ERT2tg; Hcfc1hepKO/Y livers 18 days after tamoxifen treatment (right). (A) Hematoxylin (blue) and eosin (pink)
staining. Arrows point to hepatocytes with various nuclear sizes. (B) Sections stained with DAPI (blue) together with
-catenin (red) and HCF-1 (green) antibodies. (C) Hepatic glycogen visualized by PAS staining (purple). The sections
were also stained with hematoxylin (blue). (D) DAB immunostaining for macrophage marker F4/80 (brown). The
sections were also stained with hematoxylin (blue). (E) Cryosections stained with DAPI (blue) and CD-31 antibody
(green). (F) Sections stained with DAPI (blue) and smooth-muscle -actin (SMA; green) antibody. (G) Sections
stained with Sirius red. The arrows point to collagen ﬁbers. (H) TUNEL assay of apoptotic cells (red) costained with
HCF-1 antibody (green). TUNEL-positive apoptotic cells are shown in red. (I) Electron microscopic images of control
liver (0d) and knockout Alb-Cre-ERT2tg; Hcfc1hepKO/Y male liver samples 4, 7, and 14 days after tamoxifen treatment.
Scale bars: 100 m (A to H) and 2 m (I).
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NASH during late-stage NAFLD (reviewed in reference 2). Consistent with the
Hcfc1hepKO/Y male disease progression reﬂecting NAFLD, we observed (i) a progressive
increase in the macrophage inﬂammatory marker F4/80 by 7 days (Fig. S7) and major
clusters of F4/80-positive macrophages throughout at 18 days (Fig. 3D); (ii) extensive
vascular endothelium development (i.e., CD31 or PECAM endothelial cell marker pos-
itive) (Fig. 3E); and (iii) both activated stellate cells (i.e., smooth muscle -actin [SMA]-
positive cells) (Fig. 3F) at 18 days and progressive increase in ﬁbrosis (i.e., Sirius red
positive) beginning around 9 days (Fig. 3G and Fig. S8). In addition to these aforemen-
tioned NASH hallmarks, we observed signiﬁcant cell death (i.e., terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling [TUNEL] positive)
at 18 days (Fig. 3H).
As mitochondrial malfunction is associated with NAFLD, we examined mitochondrial
structure in liver biopsy specimens from Hcfc1hepKO/Y males by electron microscopy, as
shown in Fig. 3I and Fig. S9. Consistent with the aforementioned results with PAS (Fig.
3C), Oil Red O (Fig. 2A), and Sirius red (Fig. 3G) staining and under the lower electron
microscopy magniﬁcation images shown in Fig. S9, glycogen stores decreased and lipid
deposits and collagen ﬁber increased progressively over the 14-day time course. In
parallel, although there was no evident decrease in the number of mitochondria, they
began to display reduced numbers of cristae after 4 days, which became more evident
at 7 to 14 days after tamoxifen treatment in the Hcfc1hepKO/Y males (Fig. 3I). Indeed,
some mitochondria completely lacked cristae and were swollen and spherical in shape
after 14 days of tamoxifen treatment (Fig. 3I and Fig. S9). At the same time, there were
multiple membranes around the mitochondria (Fig. S9, arrowheads). The results of
these ultrastructural analyses are consistent with those observed in liver biopsy sam-
ples from NAFLD/NASH patients (33, 34).
In summary, the Hcfc1hepKO/Y males recapitulate several physiological, metabolic,
histological, and ultrastructural features of NAFL progression to NASH in NAFLD:
increased steatosis, tissue disorganization, abnormal hepatocellular structure, meta-
bolic disorders, inﬂammation, sinusoidal vascularization, ﬁbrosis, mitochondrial defects,
and increased cell death.
PGC1 protein, but not corresponding transcript levels, decreases upon Hcfc1
inactivation. As described in the introduction, HCF-1 is implicated in both stabilization
of PGC1, thereby promoting gluconeogenesis (28), and direct transcriptional control
through binding to a multitude of transcriptional regulators at transcriptional start sites
(18). Disruption of both PGC1 stabilization and transcriptional control could be
implicated in the NAFLD progression observed upon loss of HCF-1 in hepatocytes. Thus,
we probed disruption of each of these activities.
RNA-Seq analysis showed that PGC1-encoding mRNA levels in the liver were low
but not perturbed by the loss of HCF-1 (Fig. 4A). In contrast, PGC1 protein levels
decreased, as evidenced by the partial overall loss at 7 days in an immunoblot (Fig. 4B)
and the sharp progressive reduction observed only in hepatocytes in immunostained
samples at 7 and 14 days (compare Fig. 4C to E), a result consistent with a cell-
autonomous effect of loss of HCF-1 in hepatocytes on PGC1-protein levels. Thus,
consistent with Ruan et al. (28), loss of HCF-1 leads to loss of PGC1 protein. Owing to
the multiple roles of PGC1 in hepatocyte metabolism, including mitochondrial func-
tion and gluconeogenesis, this destabilization of PGC1 may play a role in the NAFLD
progression observed in Hcfc1hepKO/Y males. Nevertheless, loss of PGC1 does not lead
to the severe NASH or lethality observed upon loss of HCF-1 (35–37). Thus, HCF-1 likely
plays additional PGC1-independent roles that are disrupted in the Hcfc1hepKO/Y males.
To probe for these activities, we turned to an analysis of the effects of loss of HCF-1 on
gene expression.
Gene expression changes upon hepatocyte-speciﬁc loss of HCF-1. To examine
the effects of HCF-1 loss on gene expression, we compared the RNA-Seq results of
Hcfc1hepKO/Y male livers to those for control Hcfc1lox/Y male and Hcfc1hepKO/ heterozy-
gous female livers. Figure 5A shows the results of principal component analysis (PCA)
Rapid NAFLD upon Loss of HCF-1 Function in Mice Molecular and Cellular Biology
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of aggregated RNA-Seq results over the course of 14 days after tamoxifen treatment.
Before tamoxifen treatment at day 0 (D00), the Alb-Cre-ERT2tg; Hcfc1lox/Y and Hcfc1lox/Y
males are similarly positioned on the PCA plot, whereas the Alb-Cre-ERT2tg; Hcfc1lox/
heterozygous females are clearly separated, probably owing to sexual dimorphism.
FIG 4 Hcfc1hepKO/Y male livers display reduced PGC1 protein levels. (A) The total Ppargc1a transcript expression
level in control Hcfc1lox/Y (blue), Alb-Cre-ERT2tg; Hcfc1hepKO/ (green), and Alb-Cre-ERT2tg; Hcfc1hepKO/Y (red) livers.
RPKM, reads per kilobase of transcript per million mapped reads. (B) Immunoblotting with anti-PGC1 antibody
and anti-U2AF65 antibody as a loading control with liver lysates of samples collected from control (0d) liver and
Alb-Cre-ERT2tg; Hcfc1hepKO/Y male livers 7 days after tamoxifen treatment. M, molecular size (in kilodaltons). (C to
E) Immunoﬂuorescence analysis of parafﬁn-embedded sections from control (0d) liver (C) and Alb-Cre-ERT2tg;
Hcfc1hepKO/Y male livers 7 (D) and 14 (E) days after tamoxifen treatment stained with DAPI (blue) and PGC1 (red)
antibody (left) or PGC1 antibody alone (right). Arrowheads point to hepatocyte nuclei, and arrows point to
non-hepatocyte cell nuclei. Scale bars, 50 m.
Minocha et al. Molecular and Cellular Biology
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FIG 5 RNA-Seq and ChIP-Seq analyses of control and Hcfc1hepKO/Y male livers identify extensive alterations in gene expression upon loss of HCF-1. (A)
Two-dimensional PCA plot of 15,616 expressed genes for control Hcfc1lox/Y male (day 0 [D00] to D14; blue), Alb-Cre-ERT2tg; Hcfc1hepKO/ (D00 to D13, except
D02 and D09; green), and Alb-Cre-ERT2tg; Hcfc1hepKO/Y (D00 to D14; red) livers after tamoxifen treatment. The coordinates of replicate samples were averaged
and displayed as single dots, with two-dimensional standard deviations indicated with broken lines. Paths followed by the control male (blue), heterozygous
female (green), and knockout male (red) liver transcriptomes are highlighted by ovals and arrows. (B) REVIGO display of functional enrichment analysis of 654
downregulated transcripts in Hcfc1hepKO/Y livers. The P value of the color key is given. (C) GSEA results for the 654 downregulated transcripts in Hcfc1hepKO/Y livers
ranked by fold change (Hcfc1hepKO/Y versus Hcfc1lox/Y) for the four most statistically signiﬁcant HALLMARK pathways. (D) Images of the HCF-1 ChIP-Seq proﬁles
mapped on the Acly, March5, Mdh1, Mmachc, and neighboring bidirectional Acad8 and Thyn1 genes in control (0d; red) liver and Alb-Cre-ERT2tg; Hcfc1hepKO/Y
(blue) male livers 4 days after tamoxifen treatment. (E) Pie charts displaying (from left to right) (i) the ratio of TSS- versus non-TSS-associated (250 bp) HCF-1
peaks; (ii) the ratio of TSS-associated HCF-1 peaks with either a single or double (generally bidirectional) TSS; and (iii) the ratio of HCF-1-associated unidirectional
or bidirectional transcription units. (F) Summary of the RNA-Seq and ChIP-Seq analyses.
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Nevertheless, after tamoxifen treatment, the Hcfc1lox/Y males and Hcfc1hepKO/ females
follow a similar upward PCA trajectory in this plot. The similarity in gene expression
pattern between the Hcfc1lox/Y males and Hcfc1hepKO/ females over the time course of
14 days is consistent with the lack of pronounced Hcfc1hepKO/ female pathology
(Fig. 1D). In contrast, in the plot, the Hcfc1hepKO/Y males follow a distinctly different PCA
trajectory away (right and downward) from the control Hcfc1lox/Y males and
Hcfc1hepKO/ females. Thus, loss of HCF-1 causes signiﬁcant changes in liver gene
expression.
To characterize these changes, we identiﬁed the gene transcripts that are either
down- or upregulated in Hcfc1hepKO/Y males compared to control Hcfc1lox/Y males. In
this way, we eliminated many genes affected solely by the tamoxifen treatment. Thus,
we identiﬁed 654 downregulated transcripts (Table S2) and 3,392 upregulated tran-
scripts. Of the 3,392 upregulated transcripts, clustering by the Partioning Around
Medoids algorithm (PAM) (see the supplemental material) identiﬁed 521 transcripts
with elevated levels within 9 days after Hcfc1hepKO induction (called early upregulated)
(Table S3) and 2,871 with elevated levels only at 9 days and beyond Hcfc1hepKO
induction (called late upregulated) (Fig. 5F and Table S4). Because the latter set was so
numerous and late after tamoxifen treatment and, thus, unlikely to represent direct
HCF-1 effects, we did not pursue them further here.
To characterize the total downregulated and early upregulated gene sets, we
probed the Gene Ontology (GO) database (38) as listed in Tables S5 and S6, respec-
tively. The most signiﬁcant associated GO term (P value of 1.4 1019) was for the
mitochondrial cellular component term (GO:0005739) with 1,667 genes and the down-
regulated gene set. One hundred twelve downregulated and 72 upregulated genes
were associated with this GO term (Fig. S10). Figure 5B shows REVIGO graphic repre-
sentations (39), in which the semantic relationship of GO terms with P values less than
5 104 were plotted with a P value color scale (see Fig. S11 for results for early
upregulated genes). Thus, functionally related GO terms neighbor one another on the
REVIGO plot.
The GO terms for the Hcfc1hepKO/Y downregulated genes included oxidation-
reduction, mitochondrial respiratory chain complex I assembly, lipid/fatty acid metab-
olism, and transport (Fig. 5B and Table S5), all mitochondrial functions. The early
upregulated transcripts (Fig. S10B and Table S6) fell into GO terms dominated by
immune activation, consistent with the inﬂammatory response we observe by 7 days
(Fig. 3D and Fig. S7), and oxidation-reduction process, again consistent with mitochon-
drial dysfunction.
To characterize the functions of the Hcfc1hepKO/Y downregulated and early upregu-
lated genes further, we performed gene set enrichment analysis (GSEA) with the GSEA
Hallmark pathways. In the downregulated set, we identiﬁed four pathways: bile-acid
metabolism, oxidative phosphorylation, peroxisome, and fatty acid metabolism (Fig.
5C). In contrast, in the early upregulated transcript set, we identiﬁed a broad array of
pathways, including those for epithelial-to-mesenchymal transition, hypoxia, angiogen-
esis, apoptosis, tumor necrosis factor alpha signaling, inﬂammatory response, cell cycle,
p53 pathway, MTORC1 signaling, and cholesterol homeostasis (Fig. S11B). Thus, the
genes downregulated upon HCF-1 loss, i.e., genes more likely to be activated by HCF-1,
form a more coherent set of genes focused on mitochondrial function.
Multisite genomic localization of HCF-1 in the liver. To date, chromatin-bound
HCF-1 largely has been found located near transcriptional start sites (TSS), with, for
example, 743 TSS in proliferating mouse embryonic stem cells (16) and over 5,400 TSS
in proliferating human HeLa cells (17). Here, we performed chromatin immunoprecipi-
tation followed by high-throughput sequencing (ChIP-Seq) to examine HCF-1 genomic
localization in the liver at days 0 and 4 after induction of hepatocyte-speciﬁc Hcfc1 gene
disruption (summarized in Table S7); examples of transcription units with HCF-1 proﬁles
are given in Fig. 5D. After ﬁltering (see Materials and Methods), we identiﬁed 7,657
HCF-1 peaks, of which 5,690 peaks (74%) were located within 250 bp up- or down-
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stream of an annotated TSS (Fig. 5E), a number similar to that found in HeLa cells (17).
Here, we focused on the 5,690 TSS-associated HCF-1 peaks. All but 63 of the 5,690
TSS-associated HCF-1 peaks disappeared by day 4 (Table S7), as illustrated in Fig. 5D,
and nearly all of these remaining peaks reﬂected residual HCF-1 binding (Fig. S12).
Of the 5,690 TSS-associated HCF-1 peaks, 1,065 (19%) were associated with bidirec-
tional promoters (Fig. 5E) in which the HCF-1 peak was within 250 bp up- or down-
stream of two TSS. Thus, the 5,690 TSS-associated HCF-1 peaks translate into 6,654
HCF-1-associated TSS (listed in Table S8), of which 33% are associated with bidirectional
promoters (Fig. 5E). Thus, HCF-1 displays preferential binding biased for a large number
of TSS. Below, we examine the relationship between HCF-1-bound TSS and the gene
expression status (i.e., RNA-Seq levels) of the corresponding genes.
Correspondence between HCF-1-bound TSS and RNA transcript levels. Indeed,
as shown in Fig. 5F (bottom), a high percentage (86%) of HCF-1-associated transcription
units had corresponding signals in the RNA-Seq analysis, indicating that HCF-1 largely
associates with active transcription units. [Indeed, this percentage of active transcrip-
tion units is likely greater than 86%, as many of the undetected transcripts corre-
sponded to poly(A)-negative noncoding RNAs which, if synthesized, would be lost
owing to our poly(A)-containing transcript selection.] Interestingly, however, most
(3,963, or 69%) of the detected HCF-1-associated transcription units did not change
measurably as a result of loss of HCF-1. Furthermore, the proportion of down- and early
upregulated transcripts (1,175) among the changing transcripts (4,046, or 29%) does
not differ much with the same proportion among HCF-1-associated transcription units
(443 out of 1,756, or 25%) (Fig. 5F). Thus, remarkably, HCF-1 associates with many
transcription units but does not appear to play a determinant role at many of them, and
it seems similarly associated with activation or repression of transcription, as indicated
previously (17).
Loss of HCF-1 leads to a corresponding loss of mitochondrial electron trans-
port machinery. In those cases where HCF-1 is TSS associated and the corresponding
gene transcripts are down- or upregulated, there is a prima facie argument for a direct
role of HCF-1 in the regulation of their transcription status. We therefore performed GO
analyses on the 280 downregulated and 163 early upregulated genes associated with
HCF-1-bound TSS (Fig. 5F). Strikingly, 60 (21%) downregulated and 25 (15%) early
upregulated genes belonged to the GO:0005739 mitochondrial cellular component
gene set of 1,667 genes, making this gene set the most signiﬁcant GO cellular
component term for both of these two gene sets (Tables S9 and S10). Thus, there is a
preponderance of HCF-1 association with genes involved in mitochondrial function.
Figure 6A illustrates the behavior of these 60 down- and 25 early upregulated tran-
scripts with a heat map of gene expression changes over 9 days after tamoxifen
treatment. Figure 6B shows that these 85 genes are broadly involved in mitochondrial
structure and function, consistent with the broad changes observed here in mitochon-
drial morphology and metabolic activities upon loss of HCF-1.
To probe the effects of loss of HCF-1 directly on oxidative phosphorylation, a key
mitochondrial function, we used a ﬁve-antibody cocktail (called anti-OXPHOS) that
recognizes a single protein subunit within each of the ﬁve electron transport complexes
(I to V) that is labile upon complex assembly failure. As shown in Fig. 6C, the levels of
mitochondrial complex I subunit NDUFB8, complex II subunit SDHB, complex IV cata-
lytic subunit I MTCO1, and complex V subunit ATP5, but not mitochondrial complex
III core protein 2 UQCRC2, were greatly reduced in the Hcfc1hepKO/Y males by 5 days
after tamoxifen treatment. Consistent with the immunoblot analysis, tissue immuno-
staining with individual antibodies against ATP5, MTCO1, and even the marginally
reduced UQCRC2 protein showed signiﬁcant reduction in mitochondrial staining in
knockouts compared to levels in control males (Fig. S13A), which was conﬁrmed by a
reduced signal with the complete anti-OXPHOS cocktail mix (Fig. S13B). An assay for
succinate dehydrogenase (SDH) activity, also a mitochondrial activity, showed reduced
Rapid NAFLD upon Loss of HCF-1 Function in Mice Molecular and Cellular Biology
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activity in Hcfc1hepKO/Y males at 7 and 18 days after tamoxifen treatment, where only
a few active clusters were seen (Fig. S13C).
Hence, loss of HCF-1 affects expression of genes involved in mitochondrial function
and affects the assembly of electron transport chain complexes. The associated mito-
chondrial dysfunction probably results in inefﬁcient -oxidation of fatty acids, leading
to the observed increased steatosis and rapid progress from NAFLD to NASH.
Clustered activation of progenitor cell proliferation in knockout males. Upon
liver injury, surviving healthy hepatocytes are known to reenter the cell cycle and to
proliferate to restore hepatic function (40–43). However, we have previously shown in
a partial-hepatectomy liver regeneration assay that HCF-1 is essential for de novo
hepatocyte proliferation (22). Hence, upon loss of HCF-1 in the hepatocytes of resting
Hcfc1hepKO/Y male livers, the pathology may be particularly severe because of not only
their dysfunction but also their additional inability to proliferate. Nevertheless, in cases
of severe hepatic injury, where healthy hepatocytes are unable to restore hepatic
function, alternate pathways involving hepatocyte progenitor cells, generally located
near the veins, can be activated (44–48). We therefore investigated here the status of
hepatic progenitor cell activation in these knockout male livers in their late phase of
disease pathology.
Such an analysis of the Hcfc1hepKO/Y knockout male livers 18 days after tamoxifen
treatment revealed distinct clusters of HCF-1-positive cells, primarily near hepatic,
particularly portal, veins (Fig. 7A) and could be identiﬁed even by H&E staining (see the
dotted boundary in Fig. S5). Although such HCF-1-positive clusters could arise from
HCF-1-positive hepatocytes that escaped Alb-Cre-ERT2tg-induced deletion of the
Hcfc1lox allele and, thus, proliferated in response to the surrounding liver injury, it is
more likely that they result from activation of a hepatocyte progenitor pathway in part
because of their position near hepatic veins where progenitor cells reside. Furthermore,
as shown in Fig. 7B, although all the cells in these clusters are positive for the
hepatocyte-speciﬁc marker HNF4 and, thus, can be deﬁned as hepatocytes, the sizes
of their nuclei are heterogeneous, ranging from the small size associated with hepa-
tocyte progenitors to the large size of hepatocytes, suggesting an ongoing evolution
from hepatocyte progenitor to fully differentiated hepatocyte.
Indicative of functional hepatocytes, these de novo HCF-1-positive hepatocyte clus-
ters displayed low fat content (Fig. 2A, dotted boundary) and higher SDH activity (Fig.
S13C, dashed boundary). Many hepatocytes within these clusters were actively prolif-
erating, as they were positive for the cell proliferation marker Ki67, the S-phase marker
proliferating cell nuclear antigen (PCNA), and the interphase and mitotic marker histone
H3 phosphorylated at serine 10 (H3S10P) (Fig. 7C, arrows).
Cytokeratin is a marker for hepatocyte progenitors (49, 50). Thus, to probe a linkage
between the proliferating HCF-1-positive hepatocyte clusters and progenitor cells, we
performed immunostaining for cytokeratin. We found that the number of cytokeratin-
positive cells was signiﬁcantly increased near portal vein areas in Hcfc1hepKO/Y males
and that these cells were actively proliferating, as many were Ki67 positive (Fig. 7D).
Thus, the proliferating HCF-1-positive hepatocyte clusters were well positioned to have
arisen from hepatocyte progenitor cells. Indeed, Fig. 7D shows a cluster of proliferating
hepatocytes adjacent to the cytokeratin-positive cells.
Thus, although there was clear hepatic progenitor cell activation, the response was
clearly insufﬁcient to restore hepatic function for survival beyond 21 to 24 days.
Loss of HCF-1 in clustered hepatocytes leads to transient mild liver injury in
Hcfc1hepKO/ heterozygous females. As mentioned above, Hcfc1hepKO/ females
survive even though, owing to random inactivation of the X-linked Hcfc1 gene, roughly
half the hepatocytes in the liver lose HCF-1 after Hcfc1hepKO allele induction (22). Here,
we investigated further the impact of this cell-selective loss of HCF-1 on liver function.
Consistent with the loss of HCF-1 within 4 days of Hcfc1hepKO allele induction in
males, in Hcfc1hepKO/ females, patches of HCF-1-positive and -negative hepatocytes
could be observed by 4 days, and as in knockout males, the nonhepatocyte liver cell
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types remained HCF-1 positive (Fig. 8E, ovals). In contrast to the severe liver
pathology of male Hcfc1hepKO/Y mice at 18 days, however, H&E (Fig. S14A) and
-catenin immunostaining (Fig. S14B and C) of the Hcfc1hepKO/ female livers
showed only mild long-term tissue disorganization. Furthermore, liver functions
were only transiently affected. Thus, an increase in hepatic fat content at 7 days was
rapidly resolved by 11 days after Hcfc1hepKO allele induction (Fig. S15A), and peri-
odic acid-Schiff staining showed a slight decline in glycogen stores at 11 days, with
FIG 7 Progenitor cell population is activated in Hcfc1hepKO/Y male livers by 18 days after tamoxifen treatment.
Immunoﬂuorescence analyses of parafﬁn-embedded sections from Alb-Cre-ERT2tg; Hcfc1hepKO/Y male livers 18 days
after tamoxifen treatment are shown. (A) Staining with DAPI (blue) and HCF-1 antibody (green). Both low and high
magniﬁcations of the same section are shown. The arrows point to distinct HCF-1-positive clusters. (B) Staining with
DAPI (blue) as well as HNF4 (red) and HCF-1 (green) antibodies. The circle highlights a periportally located HNF4-
and HCF-1-positive hepatocyte cluster. (C) Staining with DAPI (blue) and HCF-1 (green) antibody and, in red, either
Ki67 (top), PCNA (middle), or H3S10P (bottom) antibody. Arrows point to Ki67-positive, PCNA-positive, or H3S10P-
positve hepatocytes that are also HCF-1 positive. (D) Staining with DAPI (blue) as well as Ki67 (red) and cytokeratin
(green) antibodies. White arrows point to periportal Ki67- and cytokeratin-positive cells. The yellow arrow points
to a cluster of cells with hepatocyte morphologies. pv, portal vein. Scale bars, 50 m.
Minocha et al. Molecular and Cellular Biology
March 2019 Volume 39 Issue 5 e00405-18 mcb.asm.org 14
 o
n
 February 27, 2019 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
near-normal levels observed by 18 days after Hcfc1hepKO allele induction (Fig. S14D
and S15B).
As the AST liver injury marker levels were marginally increased in Hcfc1hepKO/
females (Fig. 1D), we investigated inﬂammation and liver injury markers. Indeed, in
Hcfc1hepKO/ females, there was an increase in F4/80-positive macrophages from 9 days
after Hcfc1hepKO allele induction (Fig. S14E and S16), indicating an inﬂammatory and
eventually regenerative response to the presence of HCF-1-negative cells. Albeit an
evident inﬂammatory response, the effect on the liver structure was relatively mild, as
there was little if any activation of SMA-positive stellate cells (Fig. S14F) or deposition
of Sirius red-positive collagen ﬁbers (Fig. S14G and S17). These results indicate that
Hcfc1hepKO allele induction in heterozygous females leads to a transient liver pathology
with little lasting structural damage.
This transient liver pathology likely owes to the loss of HCF-1 function in roughly half
the hepatocytes of Hcfc1hepKO/ females. For example, coimmunostaining with anti-
OXPHOS and anti-HCF-1 showed decreased levels of OXPHOS-positive cells only in
HCF-1-negative cell clusters compared to levels in HCF-1-positive cell clusters (Fig. 8A
and B, cluster outlines). Thus, importantly, in a side-by-side comparison, the loss of
mitochondrial function is directly linked to the loss of HCF-1, supporting a cell-
autonomous role of HCF-1 in mitochondrial function.
Congruous with resolution of the liver pathology after Hcfc1hepKO allele induction in
the heterozygous females, by 1 month after Hcfc1hepKO allele induction, HCF-1-positive
hepatocytes were replacing HCF-1-negative hepatocytes (Fig. 8G). Indeed, HCF-1-
positive hepatocytes reentered the cell cycle, as evidenced by anti-Ki67 labeling of
HCF-1-positive cells (Fig. 8E to G and Fig. S18). As quantiﬁed in Fig. 8C, the percentage
of HCF-1/Ki67 double-positive hepatocytes increased over time after Hcfc1hepKO allele
induction, with a maximum at 14 days. Furthermore, in parallel, cell death detected by
TUNEL staining appeared clustered in HCF-1-negative cells in the Hcfc1hepKO/ livers at
18 days (Fig. S14H).
In summary, Hcfc1hepKO/ females experience liver injury, similar to initial stages of
NAFLD, upon clustered cell loss of HCF-1. They survive apparently owing to replace-
ment of dysfunctional HCF-1-negative hepatocytes removed by apoptosis with func-
tional HCF-1-positive cells created by cell cycle reentry and subsequent proliferation.
Hence, the heterozygote females represent a model for resolution of NAFLD.
DISCUSSION
Experimental studies of NAFLD have utilized animal models in which disease onset
is induced by either high-fat diets (for example, high-fat diet lacking methionine and
choline, essential for beta-oxidation and very-low-density lipoprotein secretion), with or
without toxic chemical insult (e.g., carbon tetrachloride), or by using genetic strains
where animals accumulate excess fat, usually in combination with high-fat diets (12–15,
51). Although all these models show fat accumulation, not all progress to advanced
stages of NAFLD, and others that do take several months to induce successfully. Hence,
the rapid 3-week progression to advanced NAFLD described here with Hcfc1hepKO/Y
males and pathology resolution observed with Hcfc1hepKO/ females should, in com-
bination, be useful alternative models for NAFLD.
The hepatocyte-speciﬁc Hcfc1 knockout in Hcfc1hepKO/Y males models the develop-
ment of terminal NASH characterized by increased steatosis, mitochondrial defects,
increased inﬂammation and cell death, hepatocyte ballooning, ﬁbrosis, progenitor cell
activation, and metabolic dysfunction. In the absence of functional hepatocytes, pro-
genitor cells near hepatic veins proliferate, forming small areas of newly formed
hepatocytes characterized by the presence of increased proliferation markers, de-
creased lipid content, and normal mitochondrial activity (Fig. 7). Although, by their
location near hepatic veins, these progenitors may well represent hybrid periportal
hepatocytes (45), we have not made a direct determination here. The newly generated
hepatocytes, however, fail to restore full liver function, and the mice succumb to
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FIG 8 HCF-1-positive hepatocytes proliferate and replace HCF-1-negative hepatocytes in Hcfc1hepKO/ heterozy-
gous (HET) females. (A and B) Immunoﬂuorescence analysis of parafﬁn-embedded sections from control (0d) liver
(A) and Alb-Cre-ERT2tg; Hcfc1hepKO/ liver 7 days after tamoxifen treatment (B) stained with DAPI (blue) as well as
OXPHOS (red) and HCF-1 (green) antibodies. In panel B, HCF-1-positive (green) and HCF-1-negative (white) clusters
are outlined. (C) Percentages of HCF-1-postive-hepatocytes that are Ki67 positive (cycling) in control (n  3), and
tamoxifen-treated Hcfc1hepKO/ livers after 4 days (n  3), 7 days (n  3), 14 days (n  2), 18 days (n  3),
and 1 month (n  2). The differences between percentages of Ki67-positive HCF-1-positive hepatocytes between
0 and 4 days (P value of 0.006), 4 and 7 days (P value of 0.03), 7 and 14 days (P value of 0.03), 14 and 18 days (P
value of 0.02), and 18 days and 1 month (P value of 0.03) after tamoxifen treatment were signiﬁcant. (D to G)
Immunoﬂuorescence of parafﬁn-embedded sections from control (0d) liver (D) and Alb-Cre-ERT2tg; Hcfc1hepKO/
livers 4 days (E), 14 days (F), and 1 month (G) after tamoxifen treatment stained with DAPI (blue) as well as HCF-1
(green) and Ki67 (red) antibodies. Ovals point to clusters of HCF-1-negative hepatocytes. Arrows point to
HCF-1-positive, Ki67-positive hepatocytes. Scale bars, 100 m.
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terminal NASH. These Hcfc1hepKO/Y mice represent a new genetic model of NASH that
is rapidly induced without the use of any dietary supplements.
The hepatocyte-speciﬁc heterozygous Hcfc1 knockout in Hcfc1hepKO/ females mod-
els rapid resolution of liver injury characterized by steatosis and ﬁbrosis as well as
inﬂammation. Remaining HCF-1-positive cells rapidly replace the injured HCF-1-
negative cells, and livers revert to normal architecture and function within about a
month. In addition to permitting the study of a resolution response, these mice offer
the added advantage of the possibility of studying proliferative (in HCF-1-positive
patches) and apoptotic (in HCF-1-negative patches) hepatocytes within the same
overall liver environment. Such a genetically induced model of NAFLD displaying rapid
resolution is not currently available.
Soon after induction of complete hepatocyte-speciﬁc loss of HCF-1 in Hcfc1hepKO/Y
males, there is increased steatosis accompanied by an alteration in mitochondrion-
related gene expression levels, which is soon followed by metabolic dysfunction. Genes
downregulated upon loss of HCF-1 are most signiﬁcantly involved in mitochondrial
structure and function, including oxidation-reduction, whereas the genes that are
upregulated upon loss of HCF-1 are involved in stress responses, such as innate
immune response seen upon injury. Dysfunctional mitochondrial activities are known
to play a key role in the pathogenesis of NAFLD and the transition to NASH. Hence, our
results suggest that a primary reason for rapid progression of Hcfc1hepKO/Y male mice
to advanced NAFLD stages is mitochondrial dysfunction.
HCF-1 roles in hepatocyte function. HCF-1 likely plays multiple roles in liver
physiology via at least two avenues: the stabilization of PGC1 protein and regulation
of gene transcription.
Probably one reason Hcfc1hepKO/Y male mice progress rapidly through NAFL to
terminal NASH owes to the destabilization of PGC1 protein by the absence of HCF-1,
as shown here and by Ruan et al. (28). Indeed, there are many similarities between
PGC1 knockout mice and Hcfc1hepKO/Y male mice, including impairment of gluconeo-
genesis, increased fat accumulation, downregulation of genes involved in fatty acid
oxidation, and increased inﬂammation (37, 52, 53). However, the PGC1 knockout mice
are not terminally ill and do not progress to NASH, whereas Hcfc1hepKO/Y male mice do.
Thus, inactivation of a second role of HCF-1 is likely to be responsible for the more
severe phenotype associated with loss of HCF-1.
Loss of HCF-1 leads to a gross disruption of gene expression, as evidenced by the
marked changes in gene transcript levels soon after induction of HCF-1 loss. Further-
more, the ChIP-seq results show that HCF-1 is principally associated with the TSS of
transcriptionally active genes, as evidenced by the detection of corresponding gene
transcripts. Thus, we suggest that a second important function of HCF-1 in hepatocytes
is in transcriptional regulation.
Nevertheless, this role is curious. HCF-1 is bound to a very large number of active
TSS, 5,719 detected here, yet the levels of transcript activity of less than one-third of
these HCF-1-bound TSS (31%) change upon loss of HCF-1. Thus, there is clearly no
apparent absolute requirement for HCF-1 to maintain activated or repressed levels of
gene transcription of most HCF-1-associated transcription units. Rather, it may be
commonly associated with transcriptional regulatory promoter complexes but only
directly inﬂuence transcriptional regulation of a subset of these. In the context of
hepatocytes, however, this subset is enriched in genes involved in a wide variety of
mitochondrion-associated functions, which apparently leads to rapid liver dysfunction
upon its disappearance.
Whichever the case, after long being known for its role in cell proliferation (19), this
study illustrates the life-sustaining role HCF-1 can play in the functions of a differen-
tiated tissue, the resting adult liver. Thus, HCF-1 critically potentiates the cellular
functions of both proliferating and nonproliferating cells through a multiplicity of
mechanisms yet to be fully elucidated.
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MATERIALS AND METHODS
Mice. All experimental studies have been performed in compliance with EU and national legislation
rules, as advised by the Lemanique Animal Facility Network (Resal), concerning ethical considerations of
transportation, housing, strain maintenance, breeding, and experimental use of animals.
Homozygous mice bearing the Hcfc1 conditional (lox) allele are referred to as Hcfc1lox/lox (22). The
Hcfc1lox allele becomes the Hcfc1cKO allele in the presence of Cre recombinase, encoding a highly
truncated 66-amino-acid-long HCF-1 protein (22).
Other strains used in this study include wild-type C57BL/6 mice and Alb-Cre-ERT2tg transgenic mice
(54) (a gift from Daniel Metzger, IGBMC Strasbourg).
Females and littermate males were housed four or ﬁve per cage at 23°C, with a 12-h/12-h light/dark
cycle and ad libitum access to water and food. Tamoxifen treatment and all tissue collections were
performed at ZT2 to -3, where ZT0 is the start of the light period.
DNA isolation and genotyping. For genotyping, genomic DNA was isolated from postnatal mouse
ear tags as previously described (55). Samples were used for PCR ampliﬁcation with speciﬁc primer sets
using the KAPA2G Fast HotStart genotyping PCR mix (no. KK5621).
Tamoxifen induction. Control female Hcfc1lox/ and male Hcfc1lox/Y mice and test female Alb-Cre-
ERT2tg; Hcfc1lox/ and male Alb-Cre-ERT2tg; Hcfc1lox/Y mice (10 to 14 weeks old) were administered
intraperitoneal injections of 1 mg/mouse tamoxifen (100 l of 10 mg/ml [1:10 ethanol-corn oil]; 10540-
29-1; Sigma-Aldrich) three times at 24-h intervals from day 0 to day 2.
Tissue histology and immunohistochemistry. For ﬂuorescence and diaminobenzidine (DAB) im-
munostaining and colorations (H&E, PAS, and Sirius red stainings and TUNEL assay), the liver tissues were
sectioned into 4-m-thick parafﬁn sections. For immunostaining, sections were incubated overnight with
the respective primary antibodies. For Oil Red O staining and succinate dehydrogenase assay, the liver
tissues were sectioned into 8-m-thick cryosections. Additional details are provided in the supplemental
material.
Immunoblotting. Freshly isolated liver tissue (100 mg) was homogenized in radioimmunoprecipi-
tation assay buffer and protein concentrations were determined. Additional details are provided in the
supplemental material.
Quantitation and statistical analyses. For each analysis, all cells in a representative ﬁeld of
4-m-thick parafﬁn sections were counted. Student’s t tests were performed by using the R package
(www.r-project.org).
Data availability. We declare that the data supporting the ﬁndings of this study are available within
the paper and in the supplemental material.
SUPPLEMENTAL MATERIAL
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